Afimkibart
RVT-3101 / PRA023Roche's TL1A acquired from Roivant's Telavant in Oct 2023 for $7.1B. Six active P3s in IBD plus expansion to AD and RA.
Target: TNFSF15 monoclonal antibody (anti-TL1A) Hoffmann-La Roche Inflammation
When will we know if it works?
Fresh est.A positive readout makes TNFSF15 a validated target for the first time. Hover the badge above for what the confidence level means.
6
Phase 3 trials
6 active · 0 completed
10
Total trials
P2: 4 · P1: 0
600
Max trial size
across 5 indications
1
Sponsors at target
incl. 4 other assets
What does it do?
TNFSF15 — TL1A (TNF Superfamily Member 15)
Modality: monoclonal antibody (anti-TL1A)
Program: TRIBUTE
The 6 Phase 3 trials
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT06589986 | Moderately to Severely Active Ulcerative Colitis | 400 | ACTIVE_NOT_RECRUITING | 2024-09-17 | 2027-01-30 | Fresh est. |
| NCT06588855 | Moderately to Severely Active Ulcerative Colitis | 350 | RECRUITING | 2024-12-11 | 2027-01-30 | Fresh est. |
| NCT06819878 | Moderately to Severely Active Crohns Disease | 600 | RECRUITING | 2025-03-17 | 2028-12-31 | Fresh est. |
| NCT06819891 | Moderately to Severely Active Crohns Disease | 425 | RECRUITING | 2025-05-12 | 2028-12-31 | Fresh est. |
| NCT07158242 | Moderately to Severely Active Ulcerative Colitis | 100 | RECRUITING | 2026-04-15 | 2030-03-31 | Fresh est. |
| NCT07298421 | Moderately to Severely Active Crohns Disease | 100 | NOT_YET_RECRUITING | 2026-05-29 | 2030-05-31 | Fresh est. |
What deals have been done?
| Year | Type | Counterparty | Value |
|---|---|---|---|
| 2023 | acquisition | Telavant Holdings (Roivant subsidiary) | $7.1B |
What's the case for and against?
✓ What's working in its favor
- Phase 2b TUSCANY UC: induction clinical remission 32.1% vs placebo 11.1% (Pfizer-era data)
- Phase 2 atopic dermatitis program initiated 2025
Who else is racing? — 4 other assets at TNFSF15
| Asset | Sponsor | Status |
|---|---|---|
| Tulisokibart | Merck (via Prometheus $10.8B) | P3 active |
| Duvakitug (TEV-48574) | Sanofi/Teva | Positive P2 readout 2024 — P3 not yet started in our data |
| BB-TL1A-VIAL-HLE | BeiGene | P1 |
| BCD-261 | Biocad | P2 (Russia) |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.